Quick Answer
Longevity Health Holdings, Inc. reported R&D Expense of $788.9 thousand for fiscal year 2025.
Longevity Health Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $788.9K | -25.2% |
| 2024 | $1.05M | -57.8% |
| 2023 | $2.50M | +13.7% |
| 2022 | $2.20M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $228.0K | -31.3% | -12.3% |
| June 30, 2025 | $259.9K | +149.7% | +32.0% |
| March 31, 2025 | $196.9K | -54.1% | -40.7% |
| September 30, 2024 | $331.8K | -79.1% | +218.8% |
| June 30, 2024 | $104.1K | -87.4% | -75.8% |
| March 31, 2024 | $429.4K | -42.0% | -73.0% |
| September 30, 2023 | $1.59M | +178.6% | +93.2% |
| June 30, 2023 | $823.7K | — | +11.3% |
- Longevity Health Holdings, Inc. showed a decrease of -25.2% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Longevity Health Holdings, Inc.’s r&d expense has declined by 64.1% (from $2.20 million to $788.9 thousand).
- The most recent figure is from Longevity Health Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: